Find a Clinical Trial
Is a clinical trial right for you? Search our database to find studies for which you may be eligible.
Renal Tumors Classification Biology and Banking Study: Study of Kidney Tumors in Younger Patients
Study Type: Other
Phase: N/A
NCTID: NCT00898365
Principal Investigator:
Keith August
Phase I/ II Trial of Pazopanib Alternating with Bevacizumab in Treatment-Naive Metastatic Clear Cell Renal Cell Carcinoma Patients
Phase II Randomized Double Blind Trial of PF-04518600, an OX40 Antibody, in Combination with Axitinib versus Axitinib in Immune-Checkpoint Inhibitor Exposed Patients with Metastatic Renal Cell Carcinoma
Outcomes Database to prospectivelY aSSEss the changing TherapY landscape in Renal Cell Carcinoma ODYSSEY RCC
Study Type: Treatment
Phase: IV
NCTID: NCT04919122
Principal Investigator:
Elizabeth Wulff-Burchfield
A Phase III RandOmized Study Comparing PERioperative Nivolumab vs. Observation in Patients with Localized Renal Cell Carcinoma Undergoing Nephrectomy PROSPER RCC
Study Type: Treatment
Phase: III
NCTID: NCT03055013
Principal Investigator:
Elizabeth Wulff-Burchfield
A Phase II Study of AZD1775 in SETD2-Deficient Advanced Solid Tumor Malignancies
An Expanded Access Program for the non-invasive detection of clear cell renal cell carcinoma ccRCC in patients with renal masses utilizing Zirconium-labelled girentuximab 89Zr-DFO-girentuximab
Phase III Randomized Trial of Stereotactic Ablative Radiotherapy SAbR for Oligometastatic Advanced Renal Carcinoma SOAR
Study Type: Treatment
Phase: III
NCTID: NCT05863351
Principal Investigator:
Elizabeth Wulff-Burchfield
Treatment of Newly Diagnosed Diffuse Anaplastic Wilms Tumors DAWT and Relapsed Favorable Histology Wilms Tumors FHWT
Study Type: Treatment
Phase: II
NCTID: NCT04322318
Principal Investigator:
Keith August
PD-Inhibitor Nivolumab and Ipilimumab Followed by Nivolumab vs. VEGF TKI Cabozantinib with Nivolumab: A Phase III Trial in Metastatic Untreated REnal Cell CancEr [PDIGREE]
Study Type: Treatment
Phase: III
NCTID: NCT03793166
Principal Investigator:
Elizabeth Wulff-Burchfield